Author:
Kainuma Mosaburo,Funakoshi Kouta,Ouma Shinji,Yamashita Ken-ichiro,Ohara Tomoyuki,Yoshiiwa Aoi,Murata Masayuki,Tsuboi Yoshio
Funder
Japan Agency for Medical Research and Development
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference18 articles.
1. Stop Altzheimer's before it starts;McDade;Nature,2017
2. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness;Wolfson;Clin Ther,2002
3. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease;Takeda;Int J Geriatr Psychiatry,2006
4. A placebo-controlled, double-blind, comparative study of galantamine hydrobromide in patients with Alzheimer-type dementia;Honma;Jpn J Geriatr Psychiatry,2011
5. A 24-week, randomized, controlled study to evaluate the tolerability, safety and Efficacy of 2 different titration schemes of the rivastigmine patch in Japanese patients with mild to moderate Alzheimer's disease;Nakamura;Dement Geriatr Cogn Disord,2015
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献